EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 31 (2024) Parasite, 31 (2024) 56 References
Open Access
Review
Issue
Parasite
Volume 31, 2024
Article Number 56
Number of page(s) 13
DOI https://doi.org/10.1051/parasite/2024055
Published online 23 September 2024
  1. Abulaihaiti M, Wu X-W, Qiao L, Lv H-L, Zhang H-W, Aduwayi N, Wang Y-J, Wang X-C, Peng X-Y. 2015. Efficacy of albendazole-chitosan microsphere-based treatment for alveolar echinococcosis in mice. PLoS Neglected Tropical Diseases, 9, e0003950. [CrossRef] [PubMed] [Google Scholar]
  2. Albani CM, Elissondo MC. 2014. Efficacy of albendazole in combination with thymol against Echinococcus multilocularis protoscoleces and metacestodes. Acta Tropica, 140, 61–67. [CrossRef] [PubMed] [Google Scholar]
  3. Albani CM, Pensel PE, Elissondo N, Gambino G, Elissondo MC. 2015. In vivo activity of albendazole in combination with thymol against Echinococcus multilocularis. Veterinary Parasitology, 212, 193–199. [CrossRef] [PubMed] [Google Scholar]
  4. Ammann RW, Fleiner-Hoffmann A, Grimm F, Eckert J. 1998. Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. Journal of Hepatology, 29, 994–998. [CrossRef] [PubMed] [Google Scholar]
  5. Ammann RW, Stumpe KDM, Grimm F, Deplazes P, Huber S, Bertogg K, Fischer DR, Müllhaupt B. 2015. Outcome after discontinuing long-term benzimidazole treatment in 11 patients with non-resectable alveolar echinococcosis with negative FDG-PET/CT and Anti-EmII/3-10 serology. PLOS Neglected Tropical Diseases, 9, e0003964. [CrossRef] [PubMed] [Google Scholar]
  6. Antolová D, Reiterová K. 2010. Influence of Echinococcus multilocularis infection on reproduction and cellular immune response of mice. Parasite Immunology, 32, 384–387. [CrossRef] [PubMed] [Google Scholar]
  7. Autier B, Gottstein B, Millon L, Ramharter M, Gruener B, Bresson-Hadni S, Dion S, Robert-Gangneux F. 2023. Alveolar echinococcosis in immunocompromised hosts. Clinical Microbiology and Infection, 29, 593–599. [CrossRef] [PubMed] [Google Scholar]
  8. Baldolli A, Bonhomme J, Yera H, Grenouillet F, Chapon F, Barbier C, Hazera P, Verdon R. 2019. Isolated cerebral alveolar echinococcosis. Open Forum Infectious Diseases, 6, ofy349. [CrossRef] [PubMed] [Google Scholar]
  9. Bardonnet K, Vuitton DA, Grenouillet F, Mantion GA, Delabrousse E, Blagosklonov O, Miguet J-P, Bresson-Hadni S. 2013. 30-yr course and favorable outcome of alveolar echinococcosis despite multiple metastatic organ involvement in a non-immune suppressed patient. Annals of Clinical Microbiology and Antimicrobials, 12, 1. [CrossRef] [PubMed] [Google Scholar]
  10. Bartholomot G, Vuitton DA, Harraga S, Shi DZ, Giraudoux P, Barnish G, Wang YH, MacPherson CNL, Craig PS. 2002. Combined ultrasound and serologic screening for hepatic alveolar echinococcosis in central China. American Journal of Tropical Medicine and Hygiene, 66, 23–29. [CrossRef] [PubMed] [Google Scholar]
  11. Brehm K, Kronthaler K, Jura H, Frosch M. 2000. Cloning and characterization of β-tubulin genes from Echinococcus multilocularis. Molecular and Biochemical Parasitology, 107, 297–302. [CrossRef] [PubMed] [Google Scholar]
  12. Briolay T, Petithomme T, Fouet M, Nguyen-Pham N, Blanquart C, Boisgerault N. 2021. Delivery of cancer therapies by synthetic and bio-inspired nanovectors. Molecular Cancer, 20, 55. [CrossRef] [PubMed] [Google Scholar]
  13. Brunetti E, Kern P, Vuitton DA. 2010. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Tropica, 114, 1–16. [Google Scholar]
  14. Burkert S, Peters L, Bloehdorn J, Grüner B. 2022. Salvage therapy for alveolar echinococcosis-a case series. Pathogens, 11, 333. [CrossRef] [PubMed] [Google Scholar]
  15. Caoduro C, Porot C, Vuitton DA, Bresson-Hadni S, Grenouillet F, Richou C, Boulahdour H, Blagosklonov O. 2013. The role of delayed 18F-FDG PET imaging in the follow-up of patients with alveolar echinococcosis. Journal of Nuclear Medicine, 54, 358–363. [Google Scholar]
  16. Carlsson G, Patring J, Ullerås E, Oskarsson A. 2011. Developmental toxicity of albendazole and its three main metabolites in zebrafish embryos. Reproductive Toxicology, 32, 129–137. [CrossRef] [Google Scholar]
  17. Chauchet A, Grenouillet F, Knapp J, Richou C, Delabrousse E, Dentan C, Millon L, Di Martino V, Contreras R, Deconinck E, Blagosklonov O, Vuitton DA, Bresson-Hadni S, Network FrancEchino. 2014. Increased incidence and characteristics of alveolar echinococcosis in patients with immunosuppression-associated conditions. Clinical Infectious Diseases, 59, 1095–1104. [CrossRef] [PubMed] [Google Scholar]
  18. Chaudhry S, Zurbriggen R, Preza M, Kämpfer T, Kaethner M, Memedovski R, Scorrano N, Hemphill A, Doggett JS, Lundström-Stadelmann B. 2022. Dual inhibition of the Echinococcus multilocularis energy metabolism. Frontiers in Veterinary Science, 9, 981664. [CrossRef] [PubMed] [Google Scholar]
  19. Cheng Z, Xu Z, Tian H, Liu F, Li X, Luo D, Wang Y. 2020. In vitro and in vivo efficacies of the EGFR/MEK/ERK signaling inhibitors in the treatment of alveolar echinococcosis. Antimicrobial Agents and Chemotherapy, 64, e00341-20. [CrossRef] [PubMed] [Google Scholar]
  20. Dang Z, Xu S, Zhang H, Gui W, Zhao Y, Duan L, Hu W. 2018. In vitro and in vivo efficacies of carbazole aminoalcohols in the treatment of alveolar echinococcosis. Acta Tropica, 185, 138–143. [CrossRef] [PubMed] [Google Scholar]
  21. Davis A, Pawlowski ZS, Dixon H. 1986. Multicentre clinical trials of benzimidazolecarbamates in human echinococcosis. Bulletin of the World Health Organization, 64, 383–388. [PubMed] [Google Scholar]
  22. Dayan AD. 2003. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Tropica, 86, 141–159. [CrossRef] [PubMed] [Google Scholar]
  23. Dvoroznáková E, Hrcková G, Borosková Z, Velebný S, Dubinský P. 2004. Effect of treatment with free and liposomized albendazole on selected immunological parameters and cyst growth in mice infected with Echinococcus multilocularis. Parasitology International, 53, 315–325. [CrossRef] [PubMed] [Google Scholar]
  24. Eberhardt N, Peters L, Kapp-Schwoerer S, Beer M, Beer AJ, Grüner B, Thaiss WM. 2022. 18F-FDG-PET/MR in alveolar echinococcosis: multiparametric imaging in a real-world setting. Pathogens, 11, 348. [CrossRef] [PubMed] [Google Scholar]
  25. Eckardt K, Kaltenhäuser J, Kilb C, Seiler A, Stahlmann R. 2012. Relative potency of albendazole and its sulfoxide metabolite in two in vitro tests for developmental toxicity: the rat whole embryo culture and the mouse embryonic stem cell test. Reproductive Toxicology, 34, 378–384. [CrossRef] [Google Scholar]
  26. Enkai S, Inaoka DK, Kouguchi H, Irie T, Yagi K, Kita K. 2020. Mitochondrial complex III in larval stage of Echinococcus multilocularis as a potential chemotherapeutic target and in vivo efficacy of atovaquone against primary hydatid cysts. Parasitology International, 75, 102004. [CrossRef] [PubMed] [Google Scholar]
  27. Enkai S, Kouguchi H, Inaoka DK, Irie T, Yagi K, Kita K. 2021. In vivo efficacy of combination therapy with albendazole and atovaquone against primary hydatid cysts in mice. European Journal of Clinical Microbiology & Infectious Diseases, 40, 1815–1820. [CrossRef] [PubMed] [Google Scholar]
  28. Fabbri J, Pensel PE, Albani CM, Lopez LM, Simonazzi A, Bermudez JM, Palma SD, Elissondo MC. 2020. Albendazole solid dispersions against alveolar echinococcosis: a pharmacotechnical strategy to improve the efficacy of the drug. Parasitology, 147, 1026–1031. [CrossRef] [PubMed] [Google Scholar]
  29. Gao H-J, Sun X-D, Luo Y-P, Pang H-S, Ma X-M, Zhang T, Jing T, Hu W, Shen Y-J, Cao J-P. 2021. Anti-echinococcal effect of verapamil involving the regulation of the calcium/calmodulin-dependent protein kinase II response in vitro and in a murine infection model. Parasites & Vectors, 14, 108. [CrossRef] [PubMed] [Google Scholar]
  30. Gottstein B, Lachenmayer A, Beldi G, Wang J, Merkle B, Vu XL, Kurath U, Müller N. 2019. Diagnostic and follow-up performance of serological tests for different forms/courses of alveolar echinococcosis. Food and Waterborne Parasitology, 16, e00055. [CrossRef] [PubMed] [Google Scholar]
  31. Gottstein B, Wang J, Boubaker G, Marinova I, Spiliotis M, Müller N, Hemphill A. 2015. Susceptibility versus resistance in alveolar echinococcosis (larval infection with Echinococcus multilocularis). Veterinary Parasitology, 213, 103–109. [CrossRef] [PubMed] [Google Scholar]
  32. Graeter T, Eberhardt N, Shi R, Schmidberger J, Beer AJ, Beer M, Henne-Bruns D, Hillenbrand A, Barth TFE, Grimm J, Kratzer W, Gruener B. 2020. Hepatic alveolar echinococcosis: correlation between computed tomography morphology and inflammatory activity in positron emission tomography. Scientific Reports, 10, 11808. [CrossRef] [PubMed] [Google Scholar]
  33. Graeter T, Kratzer W, Oeztuerk S, Haenle MM, Mason RA, Hillenbrand A, Kull T, Barth TF, Kern P, Gruener B. 2016. Proposal of a computed tomography classification for hepatic alveolar echinococcosis. World Journal of Gastroenterology, 22, 3621–3631. [CrossRef] [PubMed] [Google Scholar]
  34. Hemer S, Brehm K. 2012. In vitro efficacy of the anticancer drug imatinib on Echinococcus multilocularis larvae. International Journal of Antimicrobial Agents, 40, 458–462. [CrossRef] [PubMed] [Google Scholar]
  35. Hemphill A, Stadelmann B, Rufener R, Spiliotis M, Boubaker G, Müller J, Müller N, Gorgas D, Gottstein B. 2014. Treatment of echinococcosis: albendazole and mebendazole – What else? Parasite, 21, 70. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  36. Hu C, Liu Z, Liu C, Li J, Wang Z, Xu L, Chen C, Fan H, Qian F. 2019. Enhanced oral bioavailability and anti-echinococcosis efficacy of albendazole achieved by optimizing the “spring” and “parachute”. Molecular Pharmaceutics, 16, 4978–4986. [CrossRef] [PubMed] [Google Scholar]
  37. Hu C, Liu Z, Liu C, Zhang Y, Fan H, Qian F. 2020. Improvement of antialveolar echinococcosis efficacy of albendazole by a novel nanocrystalline formulation with enhanced oral bioavailability. ACS Infectious Diseases, 6, 802–810. [CrossRef] [PubMed] [Google Scholar]
  38. Huang X, Wiehr S, Wild A-M, Voßberg P, Hoffmann W, Grüner B, Köhler C, Soboslay PT. 2018. The effects of taxanes, vorinostat and doxorubicin on growth and proliferation of Echinococcus multilocularis metacestodes assessed with magnetic resonance imaging and simultaneous positron emission tomography. Oncotarget, 9, 9073–9087. [CrossRef] [PubMed] [Google Scholar]
  39. Hübner C, Wiehr S, Kocherscheidt L, Wehrl H, Pichler BJ, Schmid A, Kern P, Soboslay PT. 2010. Effects of in vitro exposure of Echinococcus multilocularis metacestodes to cytostatic drugs on in vivo growth and proliferation of the parasite. Parasitology Research, 107, 459–463. [CrossRef] [PubMed] [Google Scholar]
  40. Ingold K, Bigler P, Thormann W, Cavaliero T, Gottstein B, Hemphill A. 1999. Efficacies of albendazole sulfoxide and albendazole sulfone against In vitro-cultivated Echinococcus multilocularis metacestodes. Antimicrobial Agents and Chemotherapy, 43, 1052–1061. [CrossRef] [PubMed] [Google Scholar]
  41. Jelicic K, Papic N, Viskovic K, Vince A. 2023. Case Report: Amphotericin B and mefloquine as a salvage treatment of alveolar echinococcosis. American Journal of Tropical Medicine and Hygiene, 108, 581–583. [CrossRef] [PubMed] [Google Scholar]
  42. Joekel DE, Lundström-Stadelmann B, Müllhaupt B, Hemphill A, Deplazes P. 2018. Evaluation of kinase-inhibitors nilotinib and everolimus against alveolar echinococcosis in vitro and in a mouse model. Experimental Parasitology, 188, 65–72. [CrossRef] [PubMed] [Google Scholar]
  43. Joo H, Lee J, Maskery BA, Park C, Alpern JD, Phares CR, Weinberg M, Stauffer WM. 2021. The effect of drug pricing on outpatient payments and treatment for three soil-transmitted helminth infections in the United States, 2010–2017. American Journal of Tropical Medicine and Hygiene, 104, 1851–1857. [CrossRef] [PubMed] [Google Scholar]
  44. Jura H, Bader A, Frosch M. 1998. In vitro activities of benzimidazoles against Echinococcus multilocularis metacestodes. Antimicrobial Agents and Chemotherapy, 42, 1052–1056. [CrossRef] [PubMed] [Google Scholar]
  45. Kern P, Abboud P, Kern W, Stich A, Bresson-Hadni S, Guerin B, Buttenschoen K, Gruener B, Reuter S, Hemphill A. 2008. Critical appraisal of nitazoxanide for the treatment of alveolar echinococcosis. American Journal for Tropical Medicine and Hygiene, 79, 119. [Google Scholar]
  46. Knapp J, Lallemand S, Monnien F, Felix S, Valmary-Degano S, Courquet S, Demonmerot F, Heyd B, Turco C, Doussot A, Bourgeois L, Bresson-Hadni S, Richou C, Millon L. 2022. Molecular diagnosis of alveolar echinococcosis in patients based on frozen and formalin-fixed paraffin-embedded tissue samples. Parasite, 29, 4. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  47. Koch S, Bresson-Hadni S, Miguet J-P, Crumbach J-P, Gillet M, Mantion G-A, Heyd B, Vuitton D-A, Minello A, Kurtz S, Clinicians European Collaborating. 2003. Experience of liver transplantation for incurable alveolar echinococcosis: a 45-case European collaborative report. Transplantation, 75, 856–863. [CrossRef] [PubMed] [Google Scholar]
  48. Koike A, Becker F, Sennhenn P, Kim J, Zhang J, Hannus S, Brehm K. 2022. Targeting Echinococcus multilocularis PIM kinase for improving anti-parasitic chemotherapy. PLOS Neglected Tropical Diseases, 16, e0010483. [CrossRef] [PubMed] [Google Scholar]
  49. Koziol U, Brehm K. 2015. Recent advances in Echinococcus genomics and stem cell research. Veterinary Parasitology, 213, 92–102. [CrossRef] [PubMed] [Google Scholar]
  50. Koziol U, Rauschendorfer T, Zanon Rodríguez L, Krohne G, Brehm K. 2014. The unique stem cell system of the immortal larva of the human parasite Echinococcus multilocularis. EvoDevo, 5, 10. [CrossRef] [PubMed] [Google Scholar]
  51. Kronenberg PA, Deibel A, Gottstein B, Grimm F, Müllhaupt B, Meyer Zu Schwabedissen C, Aitbaev S, Omorov RA, Abdykerimov KK, Minbaeva G, Usubalieva J, Siles-Lucas M, Pepe P, Rinaldi L, Spiliotis M, Wang J, Müller N, Torgerson PR, Deplazes P. 2022. Serological assays for alveolar and cystic echinococcosis-a comparative multi-test study in Switzerland and Kyrgyzstan. Pathogens, 11, 518. [CrossRef] [PubMed] [Google Scholar]
  52. Küster T, Kriegel N, Boykin DW, Stephens CE, Hemphill A. 2013. In vitro and in vivo activities of dicationic diguanidino compounds against Echinococcus multilocularis metacestodes. Antimicrobial Agents and Chemotherapy, 57, 3829–3835. [CrossRef] [PubMed] [Google Scholar]
  53. Küster T, Lense N, Barna F, Hemphill A, Kindermann MK, Heinicke JW, Vock CA. 2012. A new promising application for highly cytotoxic metal compounds: η6-areneruthenium(II) phosphite complexes for the treatment of alveolar echinococcosis. Journal of Medicinal Chemistry, 55, 4178–4188. [CrossRef] [PubMed] [Google Scholar]
  54. Küster T, Stadelmann B, Aeschbacher D, Hemphill A. 2014. Activities of fenbendazole in comparison with albendazole against Echinococcus multilocularis metacestodes in vitro and in a murine infection model. International Journal of Antimicrobial Agents, 43, 335–342. [CrossRef] [PubMed] [Google Scholar]
  55. Küster T, Stadelmann B, Hermann C, Scholl S, Keiser J, Hemphill A. 2011. In vitro and in vivo efficacies of mefloquine-based treatment against alveolar echinococcosis. Antimicrobial Agents and Chemotherapy, 55, 713–721. [CrossRef] [PubMed] [Google Scholar]
  56. Küster T, Stadelmann B, Rufener R, Risch C, Müller J, Hemphill A. 2015. Oral treatments of Echinococcus multilocularis-infected mice with the antimalarial drug mefloquine that potentially interacts with parasite ferritin and cystatin. International Journal of Antimicrobial Agents, 46, 546–551. [CrossRef] [PubMed] [Google Scholar]
  57. Lacey E. 1990. Mode of action of benzimidazoles. Parasitology Today, 6, 112–115. [CrossRef] [Google Scholar]
  58. Lassègue A, Estavoyer JM, Minazzi H, Barale T, Gillet M, Vuitton D, Miguet JP. 1984. Traitement de l’échinococcose alvéolaire humaine par le flubendazole. Étude clinique, morphologique et immunologique. Gastroenterologie Clinique et Biologique, 8, 314–320. [PubMed] [Google Scholar]
  59. Lawton P, Walchshofer N, Sarciron ME. 2001. In vitro effects of isoprinosine and a dipeptide methyl ester on Echinococcus multilocularis protoscoleces. Journal of Helminthology, 75, 251–257. [CrossRef] [PubMed] [Google Scholar]
  60. Lee J, Joo H, Maskery BA, Alpern JD, Park C, Weinberg M, Stauffer WM. 2021. Increases in anti-infective drug prices, subsequent prescribing, and outpatient costs. JAMA Network Open, 4, e2113963. [CrossRef] [PubMed] [Google Scholar]
  61. Li H, Song T, Qin Y, Liu W, Li X, Shao Y, Wen H. 2015. Efficiency of liposomal albendazole for the treatment of the patients with complex alveolar echinococcosis: a comparative analysis of CEUS, CT, and PET/CT. Parasitology Research, 114, 4175–4180. [CrossRef] [PubMed] [Google Scholar]
  62. Li J, Yang Y, Han X, Li J, Tian M, Qi W, An H, Wu C, Zhang Y, Han S, Duan L, Wang W, Zhang W. 2023. Oral delivery of anti-parasitic agent-loaded PLGA nanoparticles: enhanced liver targeting and improved therapeutic effect on hepatic alveolar echinococcosis. International Journal of Nanomedicine, 18, 3069–3085. [CrossRef] [Google Scholar]
  63. Li Z, Zhang G, Luo Y, Gao Q, Wang J, Chen C, Xu X, Zhao Y, Li T, Ma X. 2020. In vivo effect of magnetic microspheres loaded with E2-a in the treatment of alveolar echinococcosis. Scientific Reports, 10, 12589. [CrossRef] [PubMed] [Google Scholar]
  64. Liance M, Nemati F, Bories C, Couvreur P. 1993. Experience with doxorubicin-bound polyisohexylcyanoacrylate nanoparticles on murine alveolar echinococcosis of the liver. International Journal for Parasitology, 23, 427–429. [CrossRef] [PubMed] [Google Scholar]
  65. Liu C, Fan H, Guan L, Ge R, Ma L. 2021. In vivo and in vitro efficacy of crocin against Echinococcus multilocularis. Parasites & Vectors, 14, 364. [CrossRef] [PubMed] [Google Scholar]
  66. Liu C, Fan H, Ma J, Ma L, Ge R-L. 2021. In vitro and in vivo efficacy of thiacloprid against Echinococcus multilocularis. Parasites & Vectors, 14, 450. [CrossRef] [PubMed] [Google Scholar]
  67. Liu C, Han X, Lei W, Yin J-H, Wu S-L, Zhang H-B. 2019. The efficacy of an alternative mebendazole formulation in mice infected with Echinococcus multilocularis. Acta Tropica, 196, 72–75. [CrossRef] [PubMed] [Google Scholar]
  68. Liu W, Delabrousse É, Blagosklonov O, Wang J, Zeng H, Jiang Y, Wang J, Qin Y, Vuitton DA, Wen H. 2014. Innovation in hepatic alveolar echinococcosis imaging: best use of old tools, and necessary evaluation of new ones. Parasite, 21, 74. [PubMed] [Google Scholar]
  69. Liu Z, Guo X, Guo A, Zhang S, Zou Y, Wang Y, Li X, He W, Pu L, Zhang S, Zeng Q, Cai X, Wang S. 2022. HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein. EBioMedicine, 82, 104177. [CrossRef] [PubMed] [Google Scholar]
  70. Loos JA, Coccimiglio M, Nicolao MC, Rodrigues CR, Cumino AC. 2022. Metformin improves the therapeutic efficacy of low-dose albendazole against experimental alveolar echinococcosis. Parasitology, 149, 138–144. [CrossRef] [PubMed] [Google Scholar]
  71. Lopez LM, Pensel PE, Fabbri J, Albani CM, Elissondo N, Gambino G, Elissondo MC. 2022. The combination of carvacrol and albendazole enhanced the efficacy of monotherapy in experimental alveolar echinococcosis. Acta Tropica, 225, 106198. [CrossRef] [PubMed] [Google Scholar]
  72. Lötsch F, Waneck F, Auer H, Kaczirek K, Karanikas G, Ramharter M. 2017. FDG-PET/MRI in alveolar echinococcosis. International Journal of Infectious Diseases, 64, 67–68. [CrossRef] [Google Scholar]
  73. Lötsch F, Waneck F, Groger M, Auer H, Kaczirek K, Rausch I, Wadsak W, Hacker M, Lagler H, Ramharter M, Karanikas G. 2019. FDG-PET/MRI imaging for the management of alveolar echinococcosis: initial clinical experience at a reference centre in Austria. Tropical Medicine & International Health: TM & IH, 24, 663–670. [CrossRef] [PubMed] [Google Scholar]
  74. Luder PJ, Siffert B, Witassek F, Meister F, Bircher J. 1986. Treatment of hydatid disease with high oral doses of mebendazole. European Journal of Clinical Pharmacology, 31, 443–448. [CrossRef] [PubMed] [Google Scholar]
  75. Lundström-Stadelmann B, Rufener R, Ritler D, Zurbriggen R, Hemphill A. 2019. The importance of being parasiticidal… an update on drug development for the treatment of alveolar echinococcosis. Food and Waterborne Parasitology, 15, e00040. [CrossRef] [PubMed] [Google Scholar]
  76. Marquis B, Demonmerot F, Richou C, Thiéfin G, Millon L, Wallon M, Vuitton DA, Grall-Jezequel A, Grenouillet F, Epaulard O, Gervais P, Manuel O, Bresson-Hadni S, Swiss Transplant Cohort Study, FrancEchino Network. 2023. Alveolar echinococcosis in solid organ transplant recipients: a case series from two national cohorts. Parasite, 30, 9. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  77. Mathis A, Wild P, Boettger EC, Kapel CMO, Deplazes P. 2005. Mitochondrial ribosome as the target for the macrolide antibiotic clarithromycin in the helminth Echinococcus multilocularis. Antimicrobial Agents and Chemotherapy, 49, 3251–3255. [CrossRef] [PubMed] [Google Scholar]
  78. Matsumoto J, Müller N, Hemphill A, Oku Y, Kamiya M, Gottstein B. 2006. 14-3-3- and II/3-10-gene expression as molecular markers to address viability and growth activity of Echinococcus multilocularis metacestodes. Parasitology, 132, 83–94. [CrossRef] [PubMed] [Google Scholar]
  79. Memedovski R, Preza M, Müller J, Kämpfer T, Rufener R, de Souza MVN, da Silva ET, de Andrade GF, Braga S, Uldry A-C, Buchs N, Heller M, Lundström-Stadelmann B. 2023. Investigation of the mechanism of action of mefloquine and derivatives against the parasite Echinococcus multilocularis. International Journal for Parasitology: Drugs and Drug Resistance, 21, 114–124. [CrossRef] [Google Scholar]
  80. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. 2021. Engineering precision nanoparticles for drug delivery. Nature Reviews. Drug Discovery, 20, 101–124. [CrossRef] [PubMed] [Google Scholar]
  81. Nagy J, Schipper HG, Koopmans RP, Butter JJ, Boxtel CJV, Kager PA. 2002. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. American Journal of Tropical Medicine and Hygiene, 66, 260–263. [CrossRef] [PubMed] [Google Scholar]
  82. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Albendazole, in LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases. [Google Scholar]
  83. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres M del P, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin H-S. 2018. Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology, 16, 71. [CrossRef] [PubMed] [Google Scholar]
  84. Pensel P, Paredes A, Albani CM, Allemandi D, Sanchez Bruni S, Palma SD, Elissondo MC. 2018. Albendazole nanocrystals in experimental alveolar echinococcosis: Enhanced chemoprophylactic and clinical efficacy in infected mice. Veterinary Parasitology, 251, 78–84. [CrossRef] [PubMed] [Google Scholar]
  85. Porubcová J, Dvorožňáková E, Ševčíková Z. 2007. Immune response of mice to Echinococcus multilocularis infection after therapy with amphotericin B colloidal dispersion. Helminthologia, 44, 47–56. [CrossRef] [Google Scholar]
  86. Rausch R, Jentoft VL. 1957. Studies on the helminth fauna of Alaska. XXXI. Observations on the propagation of the larval Echinococcus multilocularis Leuckart, 1863, in vitro. Journal of Parasitology, 43, 1–8. [CrossRef] [Google Scholar]
  87. Reuter S, Jensen B, Buttenschoen K, Kratzer W, Kern P. 2000. Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. Journal of Antimicrobial Chemotherapy, 46, 451–456. [CrossRef] [Google Scholar]
  88. Reuter S, Beisler T, Kern P. 2010. Combined albendazole and amphotericin B against Echinococcus multilocularis in vitro. Acta Tropica, 115, 270–274. [CrossRef] [PubMed] [Google Scholar]
  89. Reuter S, Buck A, Grebe O, Nüssle-Kügele K, Kern P, Manfras BJ. 2003. Salvage treatment with amphotericin B in progressive human alveolar echinococcosis. Antimicrobial Agents and Chemotherapy, 47, 3586–3591. [CrossRef] [PubMed] [Google Scholar]
  90. Reuter S, Buck A, Manfras B, Kratzer W, Seitz HM, Darge K, Reske SN, Kern P. 2004. Structured treatment interruption in patients with alveolar echinococcosis. Hepatology, 39, 509–517. [PubMed] [Google Scholar]
  91. Reuter S, Manfras B, Merkle M, Härter G, Kern P. 2006. In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae. Antimicrobial Agents and Chemotherapy, 50, 2966–2970. [CrossRef] [PubMed] [Google Scholar]
  92. Reuter S, Merkle M, Brehm K, Kern P, Manfras B. 2003. Effect of amphotericin B on larval growth of Echinococcus multilocularis. Antimicrobial Agents and Chemotherapy, 47, 620–625. [CrossRef] [PubMed] [Google Scholar]
  93. Richter D, Richter J, Grüner B, Kranz K, Franz J, Kern P. 2013. In vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis. Parasitology Research, 112, 1655–1660. [CrossRef] [PubMed] [Google Scholar]
  94. Ricken FJ, Nell J, Grüner B, Schmidberger J, Kaltenbach T, Kratzer W, Hillenbrand A, Henne-Bruns D, Deplazes P, Moller P, Kern P, Barth TFE. 2017. Albendazole increases the inflammatory response and the amount of Em2-positive small particles of Echinococcus multilocularis (spems) in human hepatic alveolar echinococcosis lesions. PLoS Neglected Tropical Diseases, 11, e0005636. [CrossRef] [PubMed] [Google Scholar]
  95. Robinson MW, McFerran N, Trudgett A, Hoey L, Fairweather I. 2004. A possible model of benzimidazole binding to beta-tubulin disclosed by invoking an inter-domain movement. Journal of Molecular Graphics & Modelling, 23, 275–284. [CrossRef] [PubMed] [Google Scholar]
  96. Rodrigues JM, Bories C, Emery I, Fessi H, Devissaguet JP, Liance M. 1995. Development of an injectable formulation of albendazole and in vivo evaluation of its efficacy against Echinococcus multilocularis metacestode. International Journal for Parasitology, 25, 1437–1441. [CrossRef] [PubMed] [Google Scholar]
  97. Rufener R, Dick L, D’Ascoli L, Ritler D, Hizem A, Wells TNC, Hemphill A, Lundström-Stadelmann B. 2018. Repurposing of an old drug: In vitro and in vivo efficacies of buparvaquone against Echinococcus multilocularis. International Journal for Parasitology: Drugs and Drug Resistance, 8, 440–450. [CrossRef] [Google Scholar]
  98. Rufener R, Ritler D, Zielinski J, Dick L, da Silva ET, da Silva Araujo A, Joekel DE, Czock D, Goepfert C, Moraes AM, de Souza MVN, Müller J, Mevissen M, Hemphill A, Lundström-Stadelmann B. 2018. Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis. International Journal for Parasitology. Drugs and Drug Resistance, 8, 331–340. [CrossRef] [PubMed] [Google Scholar]
  99. Santa MA, Umhang G, Klein C, Grant DM, Ruckstuhl KE, Musiani M, Gilleard JS, Massolo A. 2023. It’s a small world for parasites: evidence supporting the North American invasion of European Echinococcus multilocularis. Proceedings of the Royal Society B: Biological Sciences, 290, 20230128. [CrossRef] [PubMed] [Google Scholar]
  100. Schantz PM, Van den Bossche H, Eckert J. 1982. Chemotherapy for larval echinococcosis in animals and humans: report of a workshop. Zeitschrift für Parasitenkunde, 67, 5–26. [CrossRef] [PubMed] [Google Scholar]
  101. Schipper HG, Koopmans RP, Nagy J, Butter JJ, Kager PA, Van Boxtel CJ. 2000. Effect of dose increase or cimetidine co-administration on albendazole bioavailability. American Journal of Tropical Medicine and Hygiene, 63, 270–273. [CrossRef] [PubMed] [Google Scholar]
  102. Schubert A, Koziol U, Cailliau K, Vanderstraete M, Dissous C, Brehm K. 2014. Targeting Echinococcus multilocularis stem cells by inhibition of the Polo-like kinase EmPlk1. PLoS Neglected Tropical Diseases, 8, e2870. [CrossRef] [PubMed] [Google Scholar]
  103. Shi Q, Liu C, Huo L, Tao Y, Zhang H. 2022. Silencing TUBB3 expression destroys the tegument and flame cells of Echinococcus multilocularis protoscoleces. Animals, 12, 2471. [CrossRef] [PubMed] [Google Scholar]
  104. Shuhua X, Jiqing Y, Mingjie W, Pieying J, Fanghua G, Junjie C, Wei J, Hotez P. 2002. Augmented bioavailability and cysticidal activity of albendazole reformulated in soybean emulsion in mice infected with Echinococcus granulosus or Echinococcus multilocularis. Acta Tropica, 82, 77–84. [CrossRef] [PubMed] [Google Scholar]
  105. Spicher M, Naguleswaran A, Ortega-Mora LM, Müller J, Gottstein B, Hemphill A. 2008. In vitro and in vivo effects of 2-methoxyestradiol, either alone or combined with albendazole, against Echinococcus metacestodes. Experimental Parasitology, 119, 475–482. [CrossRef] [PubMed] [Google Scholar]
  106. Spicher M, Roethlisberger C, Lany C, Stadelmann B, Keiser J, Ortega-Mora LM, Gottstein B, Hemphill A. 2008. In vitro and in vivo treatments of Echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives. Antimicrobial Agents and Chemotherapy, 52, 3447–3450. [CrossRef] [PubMed] [Google Scholar]
  107. Stadelmann B, Aeschbacher D, Huber C, Spiliotis M, Müller J, Hemphill A. 2014. Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes. PLoS Neglected Tropical Diseases, 8, e3352. [CrossRef] [PubMed] [Google Scholar]
  108. Stadelmann B, Küster T, Scholl S, Barna F, Kropf C, Keiser J, Boykin DW, Stephens CE, Hemphill A. 2011. In vitro efficacy of dicationic compounds and mefloquine enantiomers against Echinococcus multilocularis metacestodes. Antimicrobial Agents and Chemotherapy, 55, 4866–4872. [CrossRef] [PubMed] [Google Scholar]
  109. Stadelmann B, Rufener R, Aeschbacher D, Spiliotis M, Gottstein B, Hemphill A. 2016. Screening of the open source malaria box reveals an early lead compound for the treatment of alveolar echinococcosis. PLoS Neglected Tropical Diseases, 10, e0004535. [CrossRef] [PubMed] [Google Scholar]
  110. Stadelmann B, Scholl S, Müller J, Hemphill A. 2010. Application of an in vitro drug screening assay based on the release of phosphoglucose isomerase to determine the structure-activity relationship of thiazolides against Echinococcus multilocularis metacestodes. Journal of Antimicrobial Chemotherapy, 65, 512–519. [CrossRef] [PubMed] [Google Scholar]
  111. Stadelmann B, Spiliotis M, Müller J, Scholl S, Müller N, Gottstein B, Hemphill A. 2010. Echinococcus multilocularis phosphoglucose isomerase (EmPGI): a glycolytic enzyme involved in metacestode growth and parasite-host cell interactions. International Journal for Parasitology, 40, 1563–1574. [CrossRef] [PubMed] [Google Scholar]
  112. Stettler M, Siles-Lucas M, Sarciron E, Lawton P, Gottstein B, Hemphill A. 2001. Echinococcus multilocularis alkaline phosphatase as a marker for metacestode damage induced by in vitro drug treatment with albendazole sulfoxide and albendazole sulfone. Antimicrobial Agents and Chemotherapy, 45, 2256–2262. [CrossRef] [PubMed] [Google Scholar]
  113. Stettler M, Fink R, Walker M, Gottstein B, Geary TG, Rossignol JF, Hemphill A. 2003. In vitro parasiticidal effect of Nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrobial Agents and Chemotherapy, 47, 467–474. [CrossRef] [PubMed] [Google Scholar]
  114. Stettler M, Rossignol JF, Fink R, Walker M, Gottstein B, Merli M, Theurillat R, Thormann W, Dricot E, Segers R, Hemphill A. 2004. Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. International Journal for Parasitology, 34, 615–624. [PubMed] [Google Scholar]
  115. Tappe D, Müller A, Frosch M, Stich A. 2009. Limitations of amphotericin B and nitazoxanide in the treatment of alveolar echinococcosis. Annals of Tropical Medicine and Parasitology, 103, 177–181. [CrossRef] [PubMed] [Google Scholar]
  116. Taylor DH, Morris DL, Richards KS, Reffin D. 1988. Echinococcus multilocularis: in vivo results of therapy with albendazole and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene, 82, 611–615. [CrossRef] [PubMed] [Google Scholar]
  117. Vanparijs O. 1990. Chemotherapy of experimental Echinococcus multilocularis in jirds. Parasitology Research, 76, 238–240. [CrossRef] [Google Scholar]
  118. Venkatesan P. 1998. Albendazole. Journal of Antimicrobial Chemotherapy, 41, 145–147. [CrossRef] [Google Scholar]
  119. Vuitton DA, McManus DP, Rogan MT, Romig T, Gottstein B, Naidich A, Tuxun T, Wen H, da Silva AM, Vuitton DA, McManus DP, Romig T, Rogan MR, Gottstein B, da Silva AM, Wen H, Naidich A, Tuxun T, Avcioglu A, Boufana B, Budke C, Casulli A, Güven E, Hillenbrand A, Jalousian F, Jemli MH, Knapp J, Laatamna A, Lahmar S, Naidich A, Rogan MT, Sadjjadi SM, Schmidberger J, Amri M, Bellanger A-P, Benazzouz S, Brehm K, Hillenbrand A, Jalousian F, Kachani M, Labsi M, Masala G, da Silva AM, Seyed MS, Soufli I, Touil-Boukoffa C, Wang J, Zeyhle E, Aji T, Akhan O, Bresson-Hadni S, Dziri C, Gräter T, Grüner B, Haïf A, Hillenbrand A, Koch S, Rogan MT, Tamarozzi F, Tuxun T, Giraudoux P, Torgerson P, Vizcaychipi K, Xiao N, Altintas N, Lin R, Millon L, Zhang W, Achour K, Fan H, Junghanss T, Mantion GA. 2020. International consensus on terminology to be used in the field of echinococcoses. Parasite, 27, 41. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  120. Wang H, Zhang C-S, Fang B-B, Hou J, Li W-D, Li Z-D, Li L, Bi X-J, Li L, Abulizi A, Shao Y-M, Lin R-Y, Wen H. 2020. Dual role of hepatic macrophages in the establishment of the Echinococcus multilocularis metacestode in mice. Frontiers in Immunology, 11, 600635. [Google Scholar]
  121. Wang J, Goepfert C, Mueller N, Piersigilli A, Lin R, Wen H, Vuitton DA, Vuitton L, Mueller C, Gottstein B. 2018. Larval Echinococcus multilocularis infection reduces dextran sulphate sodium-induced colitis in mice by attenuating T helper type 1/type 17-mediated immune reactions. Immunology, 154, 76–88. [CrossRef] [PubMed] [Google Scholar]
  122. Wang J, Lin R, Zhang W, Li L, Gottstein B, Blagosklonov O, Lü G, Zhang C, Lu X, Vuitton DA, Wen H. 2014. Transcriptional profiles of cytokine/chemokine factors of immune cell-homing to the parasitic lesions: a comprehensive one-year course study in the liver of E. multilocularis-infected mice. PLoS ONE, 9, e91638. [CrossRef] [PubMed] [Google Scholar]
  123. Wang J, Marreros N, Rufener R, Hemphill A, Gottstein B, Lundström-Stadelmann B. 2020. Short communication: Efficacy of albendazole in Echinococcus multilocularis-infected mice depends on the functional immunity of the host. Experimental Parasitology, 219, 108013. [CrossRef] [PubMed] [Google Scholar]
  124. Weingartner M, Stücheli S, Jebbawi F, Gottstein B, Beldi G, Lundström-Stadelmann B, Wang J, Odermatt A. 2022. Albendazole reduces hepatic inflammation and endoplasmic reticulum-stress in a mouse model of chronic Echinococcus multilocularis infection. PLoS Neglected Tropical Diseases, 16, e0009192. [CrossRef] [PubMed] [Google Scholar]
  125. Wen H, New RR, Muhmut M, Wang JH, Wang YH, Zhang JH, Shao YM, Craig PS. 1996. Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine. Parasitology, 113(Pt 2), 111–121. [CrossRef] [PubMed] [Google Scholar]
  126. Whittaker C, Chesnais CB, Pion SDS, Kamgno J, Walker M, Basáñez M-G, Boussinesq M. 2022. Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis. PLOS Neglected Tropical Diseases, 16, e0010497. [CrossRef] [PubMed] [Google Scholar]
  127. Wilson JF, Rausch RL, McMahon BJ, Schantz PM. 1992. Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos. Clinical Infectious Diseases, 15, 234–249. [CrossRef] [PubMed] [Google Scholar]
  128. Xin Q, Lv W, Xu Y, Luo Y, Zhao C, Wang B, Yuan M, Li H, Song X, Jing T. 2022. 2-Deoxy-D-glucose and combined 2-Deoxy-D-glucose/albendazole exhibit therapeutic efficacy against Echinococcus granulosus protoscoleces and experimental alveolar echinococcosis. PLoS Neglected Tropical Diseases, 16, e0010618. [CrossRef] [PubMed] [Google Scholar]
  129. Xin Q, Yuan M, Li H, Lu J, Song X, Jing T. 2019. In vitro efficacy of ampelopsin against Echinococcus granulosus and Echinococcus multilocularis. Journal of Veterinary Medical Science, 81, 1853–1858. [CrossRef] [PubMed] [Google Scholar]
  130. Xin Q, Yuan M, Li H, Song X, Lu J, Jing T. 2019. In vitro and in vivo effects of 3-bromopyruvate against Echinococcus metacestodes. Veterinary Research, 50, 96. [CrossRef] [PubMed] [Google Scholar]
  131. Xin Q, Yuan M, Li H, Song X, Lu J, Jing T. 2020. In vitro effects of lonidamine and 6-aminonicotinamide against Echinococcus granulosus sensu stricto and Echinococcus multilocularis. Veterinary Research, 51, 29. [CrossRef] [PubMed] [Google Scholar]
  132. Yamashita K, Uchino J, Sato N, Furuya K, Namieno T. 1997. Establishment of a primary culture of Echinococcus multilocularis germinal cells. Journal of Gastroenterology, 32, 344–350. [CrossRef] [PubMed] [Google Scholar]
  133. Yang H-C, Zhang H-W, Yang J, Liu S-W, Zhang S-J. 2022. Autocrine osteopontin is involved in maintaining the growth and metastasis of Echinococcus multilocularis. Acta Tropica, 228, 106328. [CrossRef] [PubMed] [Google Scholar]
  134. Yarahmadov T, Wang J, Sanchez-Taltavull D, Rojas CAA, Brodie T, Büchi I, Keogh A, Gottstein B, Stroka D, Beldi G. 2022. Primary infection by E. multilocularis induces distinct patterns of cross talk between hepatic natural killer T cells and regulatory T cells in mice. Infection and Immunity, 90, e0017422. [CrossRef] [PubMed] [Google Scholar]
  135. Yuan M, Luo Y, Xin Q, Gao H, Zhang G, Jing T. 2016. Efficacy of osthole for Echinococcus granulosus in vitro and Echinococcus multilocularis in vivo. Veterinary Parasitology, 226, 38–43. [CrossRef] [PubMed] [Google Scholar]
  136. Zeugin T, Zysset T, Cotting J. 1990. Therapeutic monitoring of albendazole: a high-performance liquid chromatography method for determination of its active metabolite albendazole sulfoxide. Therapeutic Drug Monitoring, 12, 187. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.